Covid-19 roundup: CanSi­no sub­mits vac­cine to Chi­nese reg­u­la­tors; As­traZeneca says an­ti­bod­ies show ear­ly ef­fi­ca­cy against new vari­ants — re­port

CanSi­no says their sin­gle-dose Covid-19 vac­cine is 65.28% ef­fec­tive at pre­vent­ing symp­to­matic Covid-19 cas­es, and they’ve of­fi­cial­ly filed for au­tho­riza­tion with Chi­na’s Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion.

The vac­cine was 90.07% ef­fec­tive at pre­vent­ing se­vere dis­ease 28 days af­ter the sin­gle dose, ac­cord­ing to a state­ment re­port­ed by lo­cal me­dia. Ef­fi­ca­cy rates were slight­ly high­er 14 days af­ter the sin­gle dose, at 68.83% for symp­to­matic dis­ease and  95.47% for se­vere dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER